Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

Curious how this ASH abstract finding resistant mutations with Ponatinib was funded by Novartis and Bristol-Myers Squibb.

https://ash.confex.com/ash/2012/webprogram/Paper47619.html


Abstract #2436 A Niche-Based Cell Mutagenesis Assay Identifies ABL-Kinase Mutations Appearing in BCR-ABL T315I-Mutated Leukemic Cells Treated with Ponatinib

"In conclusion, our assay shows that the hematopoietic stem cell niche could play a crucial role in conferring resistance to Ponatinib, not only via the occurrence of novel mutations but also by providing survival signals. Preliminary results also suggest that the hematopoietic niche could facilitate the emergence of T315I mutation in cells expressing native BCR-ABL. These results could be important to study the mechanisms of the occurrence and selection of ABL-K mutations in patients treated with TKI including Ponatinib, and to develop niche-targeted therapies to overcome TKI-resistance in CML.

Disclosures: Turhan: Novartis, Bristol Myers Squibb: Honoraria, Research Funding."